Jump to content

Talk:Ensitrelvir

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

USA

[edit]

https://asia.nikkei.com/Spotlight/Coronavirus/Shionogi-in-talks-with-U.S.-to-supply-COVID-oral-drug 2600:1700:8660:E180:35:9F96:F2C6:2D0F (talk) 05:56, 25 April 2022 (UTC)[reply]

Approved

[edit]

https://www.shionogi.com/global/en/news/2022/11/e20221122.html

https://www.bloomberg.com/news/articles/2022-11-22/shionogi-s-covid-pill-xocova-wins-japanese-panel-backing 97.35.0.38 (talk) 15:10, 26 November 2022 (UTC)[reply]

china

[edit]

https://asia.nikkei.com/Business/Pharmaceuticals/Drugmaker-Shionogi-inks-deal-to-market-COVID-pill-in-China 172.87.166.242 (talk) 16:48, 30 December 2022 (UTC)[reply]

https://www.shionogi.com/global/en/news.html

Jun.26, 2023 Seven manufacturers sign sublicence agreements with the Medicines Patent Pool to produce generic versions of #Shionogi's COVID-19 oral antiviral ensitrelvir to increase access in low- and middle-income countries.

https://www.shionogi.com/global/en/news/2023/6/20230626-2.html

2023/06/26

Under the terms of the licence agreement, the seven selected generic manufacturers will be able to manufacture and supply ensitrelvir in 117 low- and middle-income countries (LMICs), pending regulatory authorisation or approval in those countries.

At least these countries are mentioned: Ukraine, China, South Africa.

Apr.11, 2023 Shionogi filed for Emergency Use Authorization of Ensitrelvir Fumaric Acid in Taiwan, for the Treatment of COVID-19

Apr.04, 2023 Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19

Jan.04, 2023 New Drug Application of Ensitrelvir Fumaric Acid, a Therapeutic Drug for COVID-19 Accepted for Review in South Korea

91.159.186.9 (talk) 17:14, 29 July 2023 (UTC)[reply]

south korea

[edit]

https://asia.nikkei.com/Spotlight/Coronavirus/Japan-s-Shionogi-seeks-approval-for-COVID-pill-in-South-Korea 2600:8804:6600:45:78FF:CBD5:85A4:C357 (talk) 01:30, 5 January 2023 (UTC)[reply]

Ensitrelvir (Xocova) and Nirmatrelvir (Paxlovid) are both sars2 main protease inhibitors

[edit]

Ensitrelvir (Xocova) and Nirmatrelvir (Paxlovid) are both sars2 main protease inhibitors

It should be mentioned that they have the same mechanism of action.

It is good Paxlovid has a competitor.

https://wiki.riteme.site/wiki/Nirmatrelvir/ritonavir

Other covid-19 drugs have different mechanisms, for example Molnupiravir.

91.159.186.9 (talk) 17:05, 29 July 2023 (UTC)[reply]

The structure is also quite refreshingly new. It looks nothing like a peptide -- well, maybe a tiny bit, but much less compared to Paxlovid. And the way it binds (PDB: 8DZ1​) is cool. Might be a good idea to seek out some articles about the design process (doi:10.1021/acsomega.2c03881 looks good). (Holy moly, the article says it also inhibits ExoN and RdRP.) Artoria2e5 🌉 14:21, 2 October 2023 (UTC)[reply]